Precision Neuroscience CEO on Medtronic Partnership, What's Next

Why It Matters

The collaboration accelerates a high‑bandwidth neural link that could restore digital independence for millions of paralyzed patients and create a multi‑billion‑dollar medical‑technology category.

Key Takeaways

• Implanted 83 temporary BCIs in volunteers under FDA clearance
• Partnering with Medtronic to develop commercial permanent implant
• Target addressable market: hundreds of billions for 6 million tetraplegics
• Aim for commercial launch in ~5 years, generating revenue
• Raised $180M; expects several hundred million to reach cash‑flow positive

Pulse Analysis

Precision Neuroscience is positioning itself at the forefront of the brain‑computer interface (BCI) wave, leveraging a strategic partnership with Medtronic to move from temporary, research‑grade implants to a market‑ready permanent device. The company’s FDA‑cleared, reversible system has already been placed in 83 volunteers, allowing users to operate smartphones, computers, and robotic tools solely with neural signals. By collaborating with 16 top hospitals—including Johns Hopkins and NYU—the firm is building a robust clinical pipeline that validates safety, reversibility, and real‑world utility, essential credentials for any medical‑device venture.

The commercial upside is massive. With an estimated six million people worldwide living with tetraplegia, the addressable market stretches into the hundreds of billions of dollars. Mager emphasized that insurance reimbursement, already being negotiated with CMS, Medicare, and Medicaid, will be pivotal to scaling adoption and preventing cost barriers. A five‑year horizon is projected for a permanent, FDA‑approved implant that can generate significant revenue, contingent on rigorous reliability testing and post‑market surveillance. This timeline aligns with broader industry expectations for advanced neurotechnology, where regulatory rigor often dictates market entry speed.

Financially, Precision Neuroscience has secured $180 million in funding over five years, a capital base that underwrites its multidisciplinary talent pool—from material science to low‑power AI chips. The company anticipates spending several hundred million dollars before achieving cash‑flow positivity, a cost structure comparable to other frontier med‑tech firms. As AI integration deepens, the BCI platform could evolve beyond paralysis therapy into a high‑bandwidth conduit for human‑machine collaboration, reshaping both healthcare delivery and the emerging neuro‑augmentation market.